Clinical Genomic Profiling to Identify Actionable Alterations for Very Early Relapsed Triple-Negative Breast Cancer Patients in the Chinese Population

Liye Wang
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
Qinglian Zhai
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
Qianyi Lu
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
Kaping Lee
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
Qiufan Zheng
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
Ruoxi Hong
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center
shusen Wang ( wangshs@sysucc.org.cn )
Sun Yat-Sen University Cancer Prevention and Treatment Center: Sun Yat-sen University Cancer Center

Research

Keywords: Triple-negative breast cancer, Next generation sequencing, Clinically relevant genomic alterations, Mutation, Pathway, Chinese patients

DOI: https://doi.org/10.21203/rs.3.rs-466470/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese population, and is characterized by early relapse and a complex molecular heterogeneity. Lack of targeted therapy contributes to the poorer outcomes compared with other breast cancer subtypes. Comprehensive genomic profiling helps to explore the clinically relevant genomic alterations (CRGAs) and potential therapeutic targets in very-early-relapsed TNBC patients, which are considered tumor recurrences within 24 months.

**Methods:** Formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens from 23 patients with very-early-relapsed TNBC and 13 patients with disease-free survival (DFS) more than 36 months were tested by FoundationOne CDx (F1CDx), a next-generation-sequencing-based diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, along with genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB).

**Results:** In total, 137 CRGAs were detected in the 23 very-early-relapsed TNBC patients, averaging 6 alterations per sample. The mean TMB was 4 Muts/Mb, which was higher than that in non-recurrence patients, and is statistically significant. The top-ranked altered genes were TP53 (83%), PTEN (35%), RB1 (30%), PIK3CA (26%), and BRCA1 (22%). RB1 mutation carriers had shorter DFS. Notably, 100% of these patients had at least 1 CRGA, and 87% of patients had at least 1 actionable alteration. In pathway analysis, patients who carried a mutation in the cell cycle pathway were more likely to experience very early recurrence. Strikingly, we detected 1 patient with ERBB2 amplification and 1 patient with ERBB2 exon20 insertion, both of which were missed by immunohistochemistry (IHC). We also detected novel alterations of ROS1-EPHA7 fusion for the first time, which has not been reported in breast cancer before.

**Conclusions:** The comprehensive genomic profiling can identify novel treatment targets and address the limited options in TNBC patients. Therefore, incorporating F1CDx into TNBC may shed light on novel therapeutic opportunities for these very-early-relapsed TNBC patients.

Introduction

Breast cancer is the most frequently diagnosed cancer and results in the second most common cancer mortality among the Chinese female population [1]. Abundant evidence suggests that breast cancer has clinical and molecular heterogeneity. Triple-negative breast cancer (TNBC) is immunohistochemically characterized by a lack of human epidermal growth factor receptor 2 (also defined by a lack of HER2 amplification by FISH), and estrogen receptor and progesterone receptors expression [2]. TNBC is regarded as the most aggressive breast malignancy and accounts for approximately 19% of all breast cancers in the Chinese population [3]. Compared with other types of breast cancer, TNBCs have higher histologic grades and a higher proportion of lymph node metastases (cN status) at presentation, which contributes to worse disease-free survival (DFS) and overall survival (OS) [4]. Because of the lack of specific targets
for therapy, TNBC represents a particular treatment challenge. Once diagnosed with metastatic triple-negative breast cancer, despite optimal systemic chemotherapy, few patients survive longer than 5 years [5]. Patients with early TNBC experience the peak risk of recurrence within 3 years of diagnosis [6]. Because of the heterogeneity of TNBC, personalized treatment strategies based on detecting and targeting tumor-specific alterations would be an effective treatment choice for the 60–70% of patients with TNBC who do not fully respond to chemotherapy or whose tumor progresses after chemotherapy [7].

Faced with these challenges, next-generation sequencing (NGS) provides us with molecular profiles of tumors from individual patients for the direction of treatment. NGS has increased the identification of previously unrecognized genes that also may be associated with improved therapeutic response and development of resistance to therapies. The feasibility of genomic mutation/alteration testing as a guide to treatment has been demonstrated by a multicenter, prospective trial (SAFIR01/UNICANCER) [8]. Recently, comprehensive genomic profiling (CGP) using the hybrid capture-based NGS was performed on all types of breast cancer and revealed the feasibility for finding therapy targets in patients with relapsed and refractory disease [9]. Given the inherently aggressive biological behavior of TNBC, it is reasonable to perform genetic testing on patients, especially for relapsed patients, and make treatment decisions based on genetic testing results.

Moreover, CGP can reveal specific genomic alterations associated with the biological behavior of cancer, such as the early relapse of TNBC. In the current study, we defined tumor recurrence within 24 months as very-early-relapsed TNBC. We compared the genomic features of TNBC patients who had long DFS with those of very-early-relapsed TNBC, aiming to identify predictive genomic factors in very-early-relapsed breast cancer patients. The other objective of the current study was to reveal novel treatment targets and provide clinicians with targeted therapeutic options in very-early-relapsed TNBC patients.

**Materials And Methods**

**Patient inclusion and tissue sample acquisition**

This was a retrospective study of TNBC patients with cancer treated at Sun Yat-sen University Cancer Center. Formalin-fixed paraffin-embedded (FFPE) biopsy specimens from 36 TNBC patients, including 23 very-early-relapsed TNBC patients and 13 no-recurrence TNBC patients were obtained with the approval of the Sun Yat-sen University Cancer Center (SYSUCC) Institutional Review Board. Biopsies were collected between 2012 and 2018 with consideration to the quality of FFPE specimens. Inclusion criteria were patients histologically confirmed ER-negative (less than 1%), PR-negative (less than 1%), and HER2 non-over expressing by immunohistochemistry (IHC) (0, 1) or non-amplified by fluorescence in situ hybridization (FISH). Baseline demographics and survival data were extracted from the clinical record.

**Clinical review**
Patient medical records were assessed for demographics, pathological features, adjuvant therapy received, time of recurrence, and outcomes, which were measured DFS time as defined by the time from the surgery of primary breast cancer until the diagnosis of tumor relapse.

**Genetic alteration assessment**

FFPE tumor tissue specimens from 23 very-early-relapsed TNBC patients were tested by FoundationOne CDx (F1CDx). FoundationOne CDx™ (F1CDx) is performed exclusively as a laboratory service using DNA extracted from FFPE tumor samples. The assay employed a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which underwent a whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, 1 promoter region, 1 non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also included the coding exons (Supplementary Table 1 and Supplementary Table 2). In total, the assay detected alterations in a total of 324 genes. Using the Illumina ® HiSeq 4000 platform, hybrid capture–selected libraries were sequenced to high uniform depth (targeting > 500X median coverage with > 99% of exons at coverage > 100X). Sequence data were then processed using a customized analysis pipeline designed to detect all classes of genomic alterations, including base substitutions, indels, copy number alterations including amplification and homozygous gene deletions, and selected genomic rearrangements such as gene fusions. Additionally, genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB), were reported.

**Statistical analysis**

Statistical analysis of all genes was based on a dichotomy (i.e., presence / absence of any alteration). Differences in alteration frequency and TMB between groups were determined using Chi-square and Fisher's exact test. Statistical significance was defined as a p-value less than 0.05.

**Immunohistochemistry**

Standard 5-µm paraffin-embedded tissue sections from patients no. 648 were stained using an anti-ROS1 rabbit monoclonal antibody (Abcam; clone EPMGHR2) applied at different dilutions (usually from 1:100 to 1:250).

**Fluorescence in situ hybridization (FISH)**

ROS1- EPHA7 fusion was determined by FISH testing on a 4 µm FFPE tissue specimens from patient No. 648.

Rearrangements of ROS1 (6q22) and EPHA7 (6q16) were independently detected using a laboratory-developed dual-color break-apart probe (BAP) strategy probe set. 5' and 3' of probes of ROS1 and EPHA7 were labeled with red and green fluorescence bacterial artificial chromosome (BAC), respectively. BAC clone probes flanking the target genes were obtained from Invitrogen (USA). DNA from each BAC probe was labeled with fluorochromes by nick translation. FFPE sections were deparaffinized, pretreated, and then hybridized with the denatured probes. Following overnight incubation, the slides were rinsed, stained
with 4′,6-diamidino-2-phenylindole (DAPI), mounted, and analyzed using a Nikon fluorescence microscope (Nikon ECLIPSE 80i, Japan).

**Results**

**Cohort**

A total of 36 FFPE TNBC surgery samples were obtained at the Sun Yat-sen University Cancer Center between 2013 and 2018 from 23-very-early-relapsed patients and 13 patients who did not relapse for more than 3 years after surgery.

All the 23 very-early-relapsed patients in our study suffered disease recurrence within 2 years after surgery, and the median DFS was 12 months. All the patients were females and their median age was 50.65 years with a range of 27–67 years; 87% (n = 20) of TNBCs in our study received modified radical mastectomy, and the remaining patients received a partial mastectomy. At the time of diagnosis, about 52% (n = 12) of the TNBC patients were at an early clinical stage (stage I or stage II), and 48% (n = 11) of patients were at an advanced stage (stage III). Except for 1 patient diagnosed as invasive lobular carcinoma, the other patients were invasive ductal carcinoma. Nearly half of the patients (n = 11) had visceral metastases after disease recurrence, the other patients had local recurrence and/or lymph node metastases (Table 1).
| Variable                  | Early recurrence (N = 23) | No recurrence (N = 13) | P value |
|--------------------------|---------------------------|------------------------|---------|
| Mean age at diagnosis    | 50.65                     | 46.62                  | 0.250   |
| Lymph node state         |                           |                        |         |
| Positive                 | 18 (78.2%)                | 6 (46.1%)              | 0.071   |
| Negative                 | 5 (21.7%)                 | 7 (53.9%)              |         |
| Mean tumor size          |                           |                        |         |
| T1                       | 5 (21.7%)                 | 8 (34.8%)              | 0.05    |
| T2                       | 16 (69.6%)                | 5 (21.7%)              |         |
| T3                       | 2 (8.7%)                  | 0                      |         |
| Historical grade         |                           |                        |         |
| I                        | 0                         | 0                      | 0.547   |
| II                       | 3 (13.0%)                 | 2 (8.7%)               |         |
| III                      | 18 (78.3%)                | 11 (47.8%)             |         |
| Missing                  | 2 (8.7%)                  | 0                      |         |
| Type of surgery          |                           |                        |         |
| Lumpectomy               | 3 (13.0%)                 | 2 (15.4%)              | 0.605   |
| Mastectomy               | 20 (87.0%)                | 11 (84.6%)             |         |
| Chemotherapy treatment   |                           |                        |         |
| Positive                 | 19 (82.6%)                | 13 (56.5%)             | 0.280   |
| Negative                 | 1 (4.3%)                  | 0                      |         |
| Missing                  | 3 (13.0%)                 | 0                      |         |

For the 13 TNBC patients who did not relapse for more than 3 years after surgery, the average DFS was 51.8 months.

**Mutation prevalence**

All the 36 FFPE samples were subjected to comprehensive genomic profiling. A total of 137 genomic alterations (GAs) were identified in the 23 very-early-relapsed TNBCs, with an average of 5.9 GAs per patient. Among the 13 non-relapsed TNBC patients, we detected 54 GAs in total, and the average number of GAs was 4.1. There was no difference between the 2 groups. The frequency of the GAs in a very-early-
The relapsed TNBC group is shown in Fig. 1. The most frequently altered genes were TP53 (83%), PTEN (35%), RB1 (30%), PIK3CA (26%), BRCA1 (22%), NOTCH1 (13%), MYC (13%), and CCND1 (13%) in the very-early-relapsed TNBCs (Fig. 1). Seven patients with RB1 mutations had shorter DFS than patients without RB1 mutation, which was statistically significant (HR = 0.303, p = 0.014). The 137 genomic alterations observed included 38 base substitutions (27.7%), 28 short insertions/deletions (20.4%), 46 focal amplifications (33.5%), 9 losses (6.6%), and 16 rearrangements (11.7%). In the recurrence-free group, the most frequent mutations were of TP53 (100%), ZNF703 (23.1%), PIK3CA (15.4%), and PTEN (15.4%), with the other mutations each being detected in only 1 patient. Although RB1-mutated patients had shorter DFS in the very-early-relapse group, no difference was found in the RB1 mutation frequency between the 2 groups. Type of alterations in the recurrence-free group were different compared with the very-early-relapsed TNBCs, including 20 base substitutions (37.0%), 6 short insertions/deletions (11.1%), 22 focal amplifications (40.7%), 4 losses (7.4%), and 2 rearrangements (3.7%). The percentage of short insertions/deletions and rearrangements was higher in the very-early-relapsed TNBC group but substitutions showed the opposite trend.

Compared with 2.54 Muts/Mb in the non-recurrence group, the mean TMB of the very-early-relapsed TNBCs was 4 Muts/Mb, ranging from 0 to 15 Muts/Mb, and the difference was statistically significant (Fig. 2). Except for only 1 patient who had MSI-intermediate tumor, all patients harbored microsatellite stability (MSS) tumors.

**Clinically relevant genomic alterations (CRGAs) and potential therapeutic targets**

In the very-early-relapsed TNBC group, all the patients had at least 1 CRGA, which is defined as a GA linked to drugs on the market or under evaluation in mechanism-driven clinical trials. Treatment recommendations based on GAs were suggested for 87% (20/23) of the patients according to at least 1 actionable alteration. The most frequently observed actionable alterations that were observed in the most frequently actionable targets included the following: PTEN (34.7%, n = 8), PIK3CA (26.1%, n = 6), BRCA1 (21.7%, n = 5), and CCND1 (13.0%, n = 3). We also detected 2 KRAS amplification, an ERBB2 and ERBB2 P780_Y781insGSP amplification, 2 NF1 rearrangements, and EGFR amplification, and a ROS1-EPHA7 fusion. Notably, the ROS1- EPHA7 mutation is a novel fusion, and this is the first time it has been identified in breast cancer tumors. PALB2, STK11, and FGFR2 were detected in only 1 patient in the very-early-relapsed group. Among those clinically relevant genomic alterations, 11 of 23 patients (47.8%) were detected with single actionable alterations. A proportion of 39.1% of patients (n = 9) exhibited multiple actionable alterations (Table 2). The patient with the most actionable alterations had 4 actionable alterations, including BRCA loss, CCND1 amplification, PI3KCA base substitutions, and the novel ROS1-EPHA7 fusion that was identified in breast cancer tumors for the first time.

Table 2. Actionable CRGAs and on-label and off-label targeted therapies in very early relapsed TNBC patients
| ID   | CRGAs    | ON-LABEL               | OFF-LABEL                                      |
|------|----------|------------------------|------------------------------------------------|
| 00624| PTEN     | Everolimus             | Temsirolimus                                   |
|      | BRCA1    | Olaparib, Talazoparib  | Niraparib, Rucaparib                          |
| 0625 | BRCA1    | Olaparib, Talazoparib  | Niraparib, Rucaparib                          |
| 00628| KRAS     | NA                     | Binimetinib, Cobimetinib, Trametinib           |
| 00630| BRCA1    | Olaparib, Talazoparib  | Niraparib, Rucaparib                          |
| 00632| PTEN     | Everolimus             | Temsirolimus                                   |
| 00634| PTEN     | Everolimus             | Temsirolimus                                   |
|      | PIK3CA   | Everolimus             | Temsirolimus                                   |
| 00637| ERBB2    | Ado-trastuzumab, emtansine, Pertuzumab, Trastuzumab, Trastuzumab-dkst, Trastuzumab-pkrb | Afatinib, Dacomitinib |
| 00638| PIK3CA   | Everolimus             | Temsirolimus                                   |
|      | NF1      | NA                     | Binimetinib, Cobimetinib, Trametinib           |
| 00639| FGFR2    | NA                     | Pazopanib, Ponatinib                           |
|      | PALB2    | Olaparib, Talazoparib  | Niraparib, Rucaparib                          |
| 00641| PIK3CA   | Everolimus             | Temsirolimus                                   |
|      | STK11    | Everolimus             | Temsirolimus                                   |
| 00642| PIK3CA   | Everolimus             | Temsirolimus                                   |
|      | PTEN     | Everolimus             | Temsirolimus                                   |
|      | NF1      | NA                     | Binimetinib, Cobimetinib, Trametinib           |
| 00643| ERBB2    | Ado-trastuzumab, emtansine, Pertuzumab, Trastuzumab, Trastuzumab-dkst, Trastuzumab-pkrb | Afatinib, Dacomitinib |
|      | PIK3CA   | Ado-trastuzumab, emtansine, Pertuzumab, Trastuzumab, Trastuzumab-dkst, Trastuzumab-pkrb | Temsirolimus |
| Pathway | Gene | Drugs | Drug | Gene | Drugs | Drug |
|---------|------|-------|------|------|-------|------|
| PTEN    | EGFR | Everolimus | Everolimus | PTEN | Everolimus | Everolimus |
| KRAS    | NA   | NA    | Temsirolimus | KRAS | NA    | Temsirolimus |
| BRCA1   | Olaparib, Talazoparib | Niraparib, Rucaparib | Niraparib, Rucaparib | BRCA1 | Olaparib, Talazoparib | Niraparib, Rucaparib |
| CCND1   | Abemaciclib, Palbociclib, Ribociclib | NA | NA | CCND1 | Abemaciclib, Palbociclib, Ribociclib | NA |
| PIK3CA  | Everolimus | Temsirolimus | Temsirolimus | PIK3CA | Everolimus | Temsirolimus |
| ROS1    | NA   | NA    | NA | ROS1 | NA    | NA |
| BRCA1   | Olaparib, Talazoparib | Niraparib, Rucaparib | Niraparib, Rucaparib | BRCA1 | Olaparib, Talazoparib | Niraparib, Rucaparib |
| PTEN    | Everolimus | Temsirolimus | Temsirolimus | PTEN | Everolimus | Temsirolimus |
| PTEN    | Everolimus | Temsirolimus | Temsirolimus | PTEN | Everolimus | Temsirolimus |
| PTEN    | Everolimus | Temsirolimus | Temsirolimus | PTEN | Everolimus | Temsirolimus |
| CCND1   | Abemaciclib, Palbociclib, Ribociclib | NA | NA | CCND1 | Abemaciclib, Palbociclib, Ribociclib | NA |
| CCND1   | Abemaciclib, Palbociclib, Ribociclib | NA | NA | CCND1 | Abemaciclib, Palbociclib, Ribociclib | NA |

**Pathway analysis**

We explored whether GRGAs in different genes could be clustered in some known pathways. We depicted a pathway mutation status and found the association with the clinical variables. In the very-early-relapsed TNBC group, 61%, 52%, 43%, 22%, and 17% of the very early relapsed TNBC patients in our cohort had at least 1 CRGAs in PI3K/mTOR, cell cycle, DNA repair, growth factor receptors (GFRs), and RAS/MAPK signaling pathways, respectively (Fig. 3; Table.3). About 61% cases had identified alterations in PI3K/mTOR pathway including PTEN (35%), PIK3CA (26%), PIK3C2B (13%), and STK11 (4%). For the cell cycle pathway, the most frequent GAs involved were RB1 (30.4 %) and CCND1 (13%). In addition, CCND2, CDH1, CDK12, CDK6, CDKN2A, and CDKN2B were each found in only 1 case. The mutation
frequency in the DNA repair pathway, GFR pathway, and the RAS/MAPK pathway was each depicted (Table 3). Interestingly, the mutation distribution in different signal pathways has a certain tendency. Gene mutations in the same signaling pathway were generally mutually exclusive (Fig. 3). In addition, the enrichment of mutations in different signaling pathways was associated with the initial tumor stage. For instance, stage III patients had more PI3K/mTOR and cell cycle pathway mutations; meanwhile, DNA repair pathway mutations and RAS/MAPK signaling pathway mutations are more likely to be detected in stage I and II patients (Fig. 3). In the no-recurrence group, the percentage of patients who had at least 1 CRGA in PI3K/mTOR, cell cycle, DNA repair, and GFR signaling pathways were 38.5%, 15.4%, 38.5%, and 23.1%, respectively; no alterations were found in RAS/MAPK signaling pathway. Interestingly, very-early-relapsed TNBCs had more alterations in the cell cycle pathway than the control group, which was statistically significant (Table 3).

Table 3. The Most Prevalent Genomic Alterations in pathway analysis
| Pathway        | Early recurrence TNBCs(N=23) | No recurrence TNBCs(N=13) | P value |
|---------------|------------------------------|---------------------------|---------|
| PI3K/mTOR     | 14(60.8%)                    | 4(30.8%)                  | 0.164   |
| PTEN          | 8(34.7%)                     | 2(15.4%)                  |         |
| PIK3CA        | 6(26.0%)                     | 2(15.4%)                  |         |
| PIK3C2B       | 3(13.0%)                     | 0                         |         |
| PIK3R1        | 1(4.3%)                      | 0                         |         |
| STK11         | 1(4.3%)                      | 0                         |         |
| **Cell cycle**| **12(52.1%)**                | 2(15.4%)                  | 0.039   |
| RB1           | 7(30.4%)                     | 1(7.7%)                   |         |
| CCND1         | 3(13.0%)                     | 0                         |         |
| CCNE1         | 0                            | 1(7.7%)                   |         |
| CDK12         | 1(4.3%)                      | 0                         |         |
| CCND2         | 1(4.3%)                      | 0                         |         |
| CDK6          | 1(4.3%)                      | 0                         |         |
| CDKN2B        | 1(4.3%)                      | 0                         |         |
| CDKN2A        | 1(4.3%)                      | 0                         |         |
| **DNA repair**| **10(43.4%)**                | 3(23.1%)                  | 0.292   |
| BRCA1         | 5(21.7%)                     | 1(7.7%)                   |         |
| RAD21         | 2(8.7%)                      | 1(7.7%)                   |         |
| BRCA2         | 0                            | 1(7.7%)                   |         |
| PALB2         | 1(4.3%)                      | 0                         |         |
| MSH1          | 1(4.3%)                      | 0                         |         |
| MLH1          | 1(4.3%)                      | 0                         |         |
| BRIP1         | 1(4.3%)                      | 0                         |         |
| BAP1          | 1(4.3%)                      | 0                         |         |
| **GFRs**      | **5(21.7%)**                 | 4(30.8%)                  | 0.693   |
| ERBB2         | 2(8.7%)                      | 0                         |         |
| FGFR1         | 0                            | 2(15.4%)                  |         |
|                  | 1(4.3%) | 1(7.7%) |
|------------------|---------|---------|
| EGFR             |         |         |
| IGF1R            |         |         |
| FGFR2            | 1(4.3%) | 0       |
| ROS1             | 1(4.3%) | 1(7.7%) |
| ERBB4            | 0       | 1(7.7%) |
| KIT              | 0       | 1(7.7%) |
| RAS/MAPK         | 4(17.3%)| 0(0%)   |
| KRAS             | 2(8.7%) | 0       |
| NF1              | 2(8.7%) | 0       |

**Rare ROS1 fusion in breast cancer**

Comprehensive genomic profiling analysis revealed a novel ROS1-EPHA7 rearrangement. It was found in a 60-year-old patient who was diagnosed with stage IIIC TNBC in September 2016, and the tumor recurred 9 months after surgery. This novel ROS1-EPHA7 fusion variant is generated by the fusion of introns 1–33 of ROS1 on chromosome 6q22 to extron6-17 of EPHA7 on chromosome 6q16. We performed IHC and found that ROS1 was diffusely positive in the tumor (Fig. 4A). The sequencing result was further verified by FISH using a ROS1 break-apart probe set showed the presence of a ROS1 rearrangement with the intact red-fused signal, indicating a ROS1 rearrangement (Fig. 4B).

**Discussion**

TNBC is an aggressive subtype of breast cancer that is characterized by resistance to therapy and poor patient survival. Because of the lack of direct targets for treatment currently, it is especially important to identify gene mutations that can be used as therapeutic targets in patients with TNBC. To improve patient outcomes and to optimize treatment regimens, novel therapeutic targets need to be identified.

In the present study, using the NGS technique, we aimed to identify novel gene mutations in a cohort of 23 very-early-relapsed TNBC patients to identify new direct targets for treatments. Both the NGS platform and the cancer panel genes chosen in this study were previously used in several other studies on breast cancer[10] and other types of cancers[11].

We identified 137 CRGAs in 23 very-early-relapsed TNBCs, among which TP53, PTEN, RB1, PIK3CA, BRCA1, NOTCH1, MYC, and CCND1 were the most frequently mutated genes (Fig. 1) in our cohort. Compared with previous studies in TNBC, TP53 was still the most frequently mutated gene, while the mutation frequency of PTEN and RB1 was higher than that reported in other literature[12, 13]. It has been reported that those 3 tumor suppressors are also the most frequent drivers of metastasis in diverse types of solid human cancers, not just in breast cancer[14]. Notably, our study found that 7 very-early-relapsed TNBC patients who were detected with RB1 mutations, including 4 frameshifts and 1 for each of
missense mutation, loss, and splice site, had shorter DFS than patients without RB1 mutations; this difference was statistically significant. Thus, understanding the impact of these tumor suppressors on clinical outcomes could be valuable.

**ERBB2 mutation**

Of further note, 2 of 23 patients were detected with ERBB2 mutation. One patient detected with ERBB2 amplification was diagnosed with IIIC TNBC in May 2016, and lung metastasis occurred 5 months after surgery. ERBB2 amplification implied that the anti-Her2 theory might be correct. Another patient with ERBB2 IHC (1+) was found with an ERBB2-P780_Y781insGSP mutation, the third most common HER2 exon 20 insertions in lung cancer\[15\], which indicated that anti-Her2 therapies such as neratinib and trastuzumab ado-trastuzumab emtansine (T-DM1) might benefit patients. Notably, this insertion mutant is located in the Pkinase-Tyr sequence of ERBB2. Mutations in the ERBB2 kinase domain have been identified in about 2–5% of various human cancers\[16\]. Lapatinib, which is known as a small molecule tyrosine kinase inhibitor (TKI), targeted the kinase domain of ERBB2-approved for breast cancer patients and may be resistant because of this insertion mutant\[17\]. Another ERBB2 T798I mutation that occurs in the same kinase domain has been demonstrated to cause a strong lapatinib-resistance effect by in vitro study\[17\]. However, whether the ERBB2 kinase domain mutation detected in our study could lead to clinical drug resistance or not has been validated by preclinical studies.

**Rare ROS1 fusion in breast cancer**

Comprehensive genomic profiling analysis revealed a novel ROS1-EPHA7 rearrangement. ROS1 fusion was detected in 2.59% of Chinese non-small cell lung cancer (NSCLC) patients\[18\] but has not been found in TNBC patients before. It has been reported that the objective response rate (ORR) of crizotinib in ROS1 fusion NSCLC patients was 83.3%\[19\]. Notably, further IHC and FISH testing verified the existence of this novel ROS1 fusion on the RNA and protein level, suggesting that the ROS1 fusion may have a biological function. Unfortunately, the patient experienced disease progression after 5-month vinorelbine-capecitabine-combined chemotherapy as the first-line treatment and was then lost to follow-up. Thus, the response to crizotinib could not be observed in this patient.

We also detected a majority of mutations identified in only 1 patient (Fig. 1), which can be explained by the high heterogeneity of TNBC\[20\]. These low-frequency mutations also have important clinical implications. For instance, ARID1A and MCL-1 have been related to chemotherapy sensitivity, ARID1A down-regulation has been associated with a poorer response to paclitaxel-based chemotherapy in patients with TNBC\[21\], and MCL, which is frequently co-amplified with MYC, has been associated with resistance to chemotherapy\[22, 23\] and decreased DFS\[24\]. For *in vitro* studies, the role of IKBKE, IGF1R, NOTCH3, and MDM4 in tumorigenesis and tumor metastasis have been reported\[25, 26, 27, 28\] and have provided clinicians with potential insights for understanding the biological behavior of TNBC and exploring treatment strategies for heavily treated patients.

**Pathway analysis**
The genes that were of significant interest in our study could be enriched in key signaling pathways, like the PI3K/mTOR pathway, cell cycle pathway, growth factor receptors, or DNA repair, and alterations in these genes could be a potential therapeutic target. PI3K/mTOR pathway has the highest mutation frequency. In our study, the mutation of PI3K-AKT signaling pathway included the PI3K catalytic subunits (PIK3CA, PIK3CB), PI3K regulatory subunit (PIK3R1), AKT-independent mTOR pathway activator (STK11), and the loss of PTEN. In a preclinical study, TNBC cell lines of M and LAR subtypes preferentially responded to the dual PI3K/mTOR inhibitor NVP-BEZ235. The benefit of the pan-PI3K inhibitor BKM120 in metastatic TNBC, both in monotherapy and combination therapy with PARP inhibitors, is undergoing clinical research (NCT01629615; NCT01790932; NCT01623349). The effectiveness of everolimus (the most studied blocking agent aimed at the mTOR kinase) in both primary and metastatic TNBC was confirmed by clinical trials. These promising data demonstrate that PI3K inhibitors or mTOR inhibitors may help select TNBC patients with activating mutations in the PI3K-AKT-mTOR pathway.

Some studies identified a subgroup of TNBC with a deficiency of DNA repair, mainly due to mutations or methylation of BRCA1/2, and other genes involved in DNA damage repair pathway. A clinical trial (NCT00494234) for a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, olaparib, in patients with BRCA1 or BRCA2 mutations and advanced breast cancer, provided an impressive ORR of 44%. A randomized, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (HER2)-negative metastasis breast cancer, detected a longer progression-free survival (PFS) of 7.0 months in the olaparib group than the 4.2 months (HR = 0.58, 95%CI: 0.43–0.80, p < 0.001), but no statistically significant improvement in OS. Given that most BRCA1/2 carriers are attributed to TNBC, olaparib could provide a significant benefit among TNBC patients deficient in DNA damage repair. Except for BRCA1/2, many mutations associated with TNBC are mainly distributed in DNA damage repair pathway, including the above-mentioned PALB2, RAD21, and MSH2, along with some other genes that were not detected in our study. Therapies designed for these mutated genes are scarce. It is still unclear whether these mutated genes can be treatment targets or not, but the utility of DNA cross-linking agents in combination with targeted agents has been reported to improve the curative effect for patients with DNA damage repair.

Ras/MAPK activity can be aberrantly stimulated via the copy number alterations of KRAS and somatic alterations of NF1. Preclinical studies have demonstrated that basal type breast cancer cells have an activated RAS-like transcriptional program and are significantly more sensitive to MEK inhibitors compared with luminal and HER-2 amplified lines. Treatment with MEK inhibitor caused the up-regulation of PI3K signaling, and the dual inhibition of both pathways could achieve better anti-tumor effects both in vitro and in vivo. These studies provide a rational hypothesis for patient selection in clinical trials with the aim to evaluate the clinical effect of MEK and PI3K inhibitors in TNBC. Clinical trials of EGFR-targeted TKIs targeting EGFR amplification in TNBC failed in both TKI monotherapy and in
combination with chemotherapy \cite{42,43}. It is still controversial if TNBC patients may respond to EGFR-TKI agents.

TNBCs are a highly proliferative group of tumors enriched for high expression of cell-cycle genes, although they are considered to be resistant to CDK4/6 inhibitors. As a heterogeneous disease, and early preclinical study has shown that the luminal androgen receptor (LAR) subtype of TNBC was highly sensitive to CDK4/6 inhibition both in vitro and in vivo in MDA-MB-453 LAR cell line xenografts compared with the basal-like subtype \cite{44}. Our study also illustrated that treatments that target the cell cycle pathway might be effective in selected TNBC patients.

Our study also has some limitations. Firstly, as a hospital-based retrospective study, the number of our samples was limited by sample quality and patient follow-up. Secondly, only 2 of 23 very-early-relapsed breast cancer patients were still under treatment but not with on-label targeted drugs; as a result, the efficacy of the drug predicted by FoundationOne CDx (F1CDx) cannot be determined in this study. Meanwhile, the patient with the rare ROS1 fusion was lost to follow-up, so whether crizotinib can benefit TNBC patients with ROS1 fusion was not validated in this study.

**Conclusion**

In summary, TNBC is a heterogeneous disease, and few recurrent mutations can be identified. Limited treatment options for the relapsed TNBC patients contribute to unfavorable prognosis. NGS-based comprehensive genomic profiling of DNA from breast cancer FFPE tumor tissue specimens to assess potential therapeutic targets is readily available. Target profiling showed a high frequency of genomic alterations linked to potential treatment options with approved or investigational drugs. NGS results demonstrate distinct clinically testable therapeutic hypotheses for individual patients. This innovative approach can provide access to potentially effective drugs and benefit the greatest number of patients in individualized treatment.

**Abbreviations**

TNBC
Triple-negative breast cancer
CRGAs
Clinically relevant genomic alterations
NGS
next-generation sequencing
CGP
Comprehensive genomic profiling
FFPE
Formalin-fixed paraffin-embedded
TMB
Tumor mutational burden
TKI
Tyrosine kinase inhibitor
DFS
Disease-free survival
OS
Overall survival
ORR
Objective response rate

Declarations

Ethics approval and consent to participate

The procedures in this study were approved by the Sun Yat-sen University Cancer Center (SYSUCC) Institutional Review Board.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

None of the authors have financial or other contractual agreements that might cause conflicts of interest.

Funding

The work was funded by the National Natural Science Foundation of China (U1601224; 81272896) (81602313) and the Natural Science Foundation of Guangdong (2019A1515011945).

Authors’ contributions

Conception and design of the study: SSW and RXH; Acquisition of clinical data: LYW, QLZ, QYL, KPL, QFZ; Analysis and interpretation of the data: LYW, QLZ; Manuscript drafting and revision: LYW, QLZ, SSW and RXH. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA Cancer J Clin. 2017;67: 7–30.
2. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90.
3. Lin Y, Yin W, Yan T, et al. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer. 2009;9.
4. Agarwal G, Nanda G, Lal P, et al. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? World J Surg. 2016;40:1362–72.
5. Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19:608–15.
6. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
7. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer. 2008;112:737–47.
8. Andre F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15:267–74.
9. Vasan N, Yelensky R, Wang K, et al. A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. Oncologist. 2014;19:453–8.
10. Parsons HA, Beaver JA, Cimino-Mathews A, et al. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23:379–86.
11. Ross JS, Wang K, Gay L, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015;1:40–9.
12. Lips EH, Michaut M, Hoogstraat M, et al. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res. 2015;17:134.
13. Comprehensive molecular portraits. of human breast tumours. Nature. 2012;490:61–70.
14. Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303.
15. Koga T, Kobayashi Y, Tomizawa K, et al. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer. 2018;126:72–9.
16. D’Amato V, Raimondo L, Formisano L, et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015;41:877–83.
17. Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res. 2008;14:2465–75.

18. Zhang Q, Wu C, Ding W, et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer. 2019;10:47–53.

19. Li Z, Shen L, Ding D, et al. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13:987–95.

20. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.

21. Lin YF, Tseng IJ, Kuo CJ, Lin HY, Chiu IJ, Chiu HW. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy. J Cell Mol Med. 2018;22:2458–68.

22. Lee KM, Giltnane JM, Balko JM, et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017;26:633–47.e637.

23. Wein L, Loi S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast. 2017;34(Suppl 1):27-s30.

24. Yang L, Perez AA, Fujie S, et al. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer. 2014;14:124.

25. Barbie TU, Alexe G, Aref AR, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014;124:5411–23.

26. Rota LM, Albanito L, Shin ME, et al. IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res. 2014;74:5668–79.

27. Leontovich AA, Jalalirad M, Salisbury JL, et al. NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res. 2018;20:105.

28. Miranda PJ, Buckley D, Raghu D, et al. MDM4 is a rational target for treating breast cancers with mutant p53. J Pathol. 2017;241:661–70.

29. Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106.

30. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.

31. Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018;17:99.

32. Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer[dagger]. Ann Oncol. 2014;25:1122–7.
33. Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017;3:509–15.
34. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–9.
35. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.
36. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–33.
37. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019.
38. Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123:1721–30.
39. Sabova L, Kretova M, Luciakova K. New insights into the role of NF1 in cancer. Neoplasma. 2013;60:233–9.
40. Hoeich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15:4649–64.
41. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69:565–72.
42. Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134:1149–59.
43. Finn RS, Press MF, Dering J, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009;27:3908–15.
44. Asghar US, Barr AR, Cutts R, et al. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23:5561–72.

Figures
Figure 1

The frequency of the genomic alterations (GA) in the 23 early recurrence TNBC samples
Figure 2

Tumor mutational burden in two groups
Figure 3

Representation of genomic alterations (GAs) into five functional and targetable pathways.

Figure 4

Immunohistochemistry text of ROS1 and Fluorescence in situ hybridization (FISH) test of ROS1 fusion. (A). IHC using anti-ROS1 IHC antibody in tumor samples. Overexpression of ROS1 in tumor cells was
observed. (Magnification 100X) (B). FISH split-apart probe flanking ROS1 and EPHA7 in No. 648 patient sample. Arrows indicate the break-apart probe adjacent to the ROS1-EPHA7 gene. (Magnification 1000X)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTable12.docx](https://example.com/SupplementaryTable12.docx)